A single-dose pharmacokinetic study of the antisickling agent cetiedil.
Cetiedil citrate is an antisickling agent shown to be effective in reducing the severity and duration of acute sickle cell crisis. With the use of a sensitive GC/MS assay, the pharmacokinetic profile of cetiedil was studied in normal men and in men with sickle cell anemia who were not in crisis at the time of study. A peak cetiedil concentration of 70 to 200 ng/ml was found immediately after a 30-minute drug infusion. The plasma level then gradually declined to approximately 10 ng/ml during a 3-hour distributive phase. Computer analysis of the data was most consistent with a three-compartment model. No pharmacokinetic differences were found between the normal men and the subjects with sickle cell. Because the cetiedil plasma levels achieved during this in vivo study are well below concentrations that exhibit antisickling activity in vitro, additional clinical studies will be necessary before an optimal dosing regimen can be established.
D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy / Q000378:metabolism; D001381:Azepines / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D001798:Blood Proteins / Q000378:metabolism; D002986:Clinical Trials as Topic; D008401:Gas Chromatography-Mass Spectrometry; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D011485:Protein Binding
D001381:Azepines; D001798:Blood Proteins; C006955:cetiedil